From FDG and beyond: the evolving potential of nuclear medicine

Kenji Hirata; Koji Kamagata; Daiju Ueda; Masahiro Yanagawa; Mariko Kawamura; Takeshi Nakaura; Rintaro Ito; Fuminari Tatsugami; Yusuke Matsui; Akira Yamada; Yasutaka Fushimi; Taiki Nozaki; Shohei Fujita; Tomoyuki Fujioka; Takahiro Tsuboyama; Noriyuki Fujima; Shinji Naganawa

doi:10.1007/s12149-023-01865-6

From FDG and beyond: the evolving potential of nuclear medicine

Ann Nucl Med. 2023 Nov;37(11):583-595. doi: 10.1007/s12149-023-01865-6. Epub 2023 Sep 25.

Authors

Kenji Hirata¹, Koji Kamagata², Daiju Ueda³, Masahiro Yanagawa⁴, Mariko Kawamura⁵, Takeshi Nakaura⁶, Rintaro Ito⁵, Fuminari Tatsugami⁷, Yusuke Matsui⁸, Akira Yamada⁹, Yasutaka Fushimi¹⁰, Taiki Nozaki¹¹, Shohei Fujita¹², Tomoyuki Fujioka¹³, Takahiro Tsuboyama⁴, Noriyuki Fujima¹⁴, Shinji Naganawa⁵

Affiliations

¹ Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan. khirata@med.hokudai.ac.jp.
² Department of Radiology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
³ Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
⁴ Department of Radiology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
⁵ Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
⁶ Department of Diagnostic Radiology, Kumamoto University Graduate School of Medicine, 1-1-1 Honjo Chuo-ku, Kumamoto, 860-8556, Japan.
⁷ Department of Diagnostic Radiology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
⁸ Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
⁹ Department of Radiology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-2621, Japan.
¹⁰ Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
¹¹ Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan.
¹² Department of Radiology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
¹³ Department of Diagnostic Radiology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
¹⁴ Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, N15, W5, Kita-ku, Sapporo, 060-8638, Japan.

PMID: 37749301
DOI: 10.1007/s12149-023-01865-6

Abstract

The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [¹⁷⁷Lu]-dotatate surpasses conventional treatments in terms of efficacy and side effects. This article reviews recently established evidence of FDG and non-FDG drugs and anticipates the future trajectory of nuclear medicine.

Keywords: Artificial neural; Data analysis; Fibroblast activation protein inhibitor; Fluorodeoxyglucose; Positron emission tomography; Prostate-specific membrane antigen.

Publication types

Review